Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, December 26, 2018
Lupin Limited and AbbVie announced that AbbVie has licensed Lupin’s MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program.
read more
Lupin and Mylan announced they will partner to commercialize a biosimilar to Enbrel.
read more
The Luye Life Sciences Group announced the opening of its new Boston R&D Center, the second global R&D facility set up in the United States.
read more
Lyell Immunopharma and PACT Pharma have announced a strategic partnership to jointly develop and test a next generation personalized anti-cancer T cell therapy against solid tumors.
read more
Lykan Bioscience, a contract development and manufacturing organization (CDMO) focused on cell-based therapies, and Vineti, the world’s only enterprise software platform supporting supply chain orchestration for clinical and commercial cell therapies...
read more
Wednesday, September 21, 2022
Lykan Bioscience named Barbara Ressler, Ph.D. VP of Manufacturing Process Sciences. development, process development and manufacturing science and technology (MS&T) teams.
read more
Tuesday, November 01, 2011
This advanced form of a highly purified novel vaccine, developed by a leading vaccine company in Japan promises to provide highly effective protection from a severely debilitating infection while exhibiting a superior patient safety profile.
read more
Lysogene announced it has entered into a manufacturing agreement with viral gene and cell therapy manufacturer Brammer Bio.
read more
Wednesday, August 14, 2019
M2Gen announced the appointment of Helge Bastian, Ph.D., as president and chief executive officer (CEO).
read more
Mabion S.A., a Polish biotechnology company, has signed a letter of intent (LoI) with French TechDev company Oddifact SAS to evaluate and advance MabionCD20 for potential use in rare diseases.
read more
MabPlex has established their new state of the art Process Development Center of Excellence located in La Jolla, CA with scale up capacity to 200L.
read more
Thursday, November 05, 2015
MabVax Therapeutics Holdings, a clinical-stage oncology drug development company, has completed manufacturing of the bulk clinical-quality drug substance of HuMab 5B1 in preparation for the planned initiation of two Phase I clinical trials with this ...
read more
Monday, February 05, 2024
mAbxience announced an agreement with Biosidus in which mAbxience will be responsible for the manufacture of the active ingredient Agalsidase Beta, developed by Biosidus as a biosimilar of Fabrazyme.
read more
Macro Trials, a precision research clinical platform, launched today to transform clinical trials. The company’s founders incubated Macro Trials with INITIATE Studios, a venture studio that co-creates companies at the intersection of healthcare, life...
read more
Macrogen has received GCLP (Good Clinical Laboratory Practice) accreditation from the Ministry of Food and Drug Safety (MFDS) in Korea.
read more